Komori
Results4183Mitsui Chemicals,Inc.Materials and Chemicals

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 2027 [IFRS]

Revenue and operating profit for the interim period significantly exceeded the year-earlier period. Following price revisions in response to higher raw material prices, the full-year revenue forecast was raised by ¥195.0 billion and the operating profit forecast by ¥29.0 billion.

Worth reading
69In focus
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
290
¥100 million (increase in full-year operating profit forecast)
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRS
Net Sales979,082¥ millionYear on year +20.3%Progress 46.7%
Operating profit93,764¥ millionYear on year +235.6%Progress 83.7%
Ordinary income90,581Millions of yen (interim profit before tax)Year on year +246.2%
Net income attributable to owners of the parent58,822¥ millionYear on year +650.0%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥162.71
Financial position at period-end
Total assets2,476,740¥ million
of which net assets 1,041,621 ¥ millionEquity ratio 35.9%vs. prior year-end -4.3pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+91,087
Investment-181,174
Financials+114,159
Net change+24,072

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥205,131 million
Segment revenueLife & Healthcare Solutions ¥134,564 million, Mobility Solutions ¥300,424 million, ICT Solutions ¥159,258 million, Basic & Green Materials ¥376,486 million, Other ¥8,350 million
Segment profitLife & Healthcare Solutions ¥12,742 million (core operating profit), Mobility Solutions ¥36,545 million (core operating profit), ICT Solutions ¥24,787 million (core operating profit), Basic & Green Materials ¥28,238 million (core operating profit), Other ¥258 million (core operating profit)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥2,095,000 million (YoY +25.5%)
Core operating profit¥150,000 million (YoY +50.0%)
Operating profit¥112,000 million (YoY +51.7%)
Ordinary income¥101,000 million (profit before tax)
Profit for the period¥70,000 million (YoY +49.2%)
Profit for the year attributable to owners of the parent¥53,000 million (YoY +54.2%)
Revision to Earnings ForecastRevenue ¥19,000 billion → ¥20,950 billion(+10.3%) / Core operating profit ¥1,050 billion → ¥1,500 billion(+42.9%) / Operating profit ¥830 billion → ¥1,120 billion(+34.9%) / Profit for the period ¥550 billion → ¥700 billion(+27.3%) / Profit for the year attributable to owners of the parent ¥450 billion → ¥530 billion(+17.8%)
Annual Dividend Forecast¥75 per share (adjusted for the stock split) → ¥75 per share (adjusted for the stock split)(0.0%)
Factors Behind Changes in Business Performance

Revenue increased due to price revisions in response to higher raw material prices, including naphtha, and foreign exchange differences. Core operating profit increased due to improved inventory valuation gains and losses and improved terms of trade resulting from price revisions. At the segment level, the factors cited include the consolidation of Ultradent as a subsidiary, the benefits of integrating the domestic polyolefin business, business structure improvements, and improved terms of trade resulting from higher raw material prices.

Disclosure regarding the going concern assumption

No applicable items

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 21 / Company name MC Dental Holdings America, Inc., Ultradent Products, Inc. and 19 subsidiaries / Excluded Number of companies 0 / Company name No
Material subsequent eventsA share transfer agreement for JSR Corporation was signed, and the transaction to make JSR Corporation a consolidated subsidiary was approved on 9 November 2026. The acquisition price is expected to be ¥1.84 trillion, with completion targeted for the second half of fiscal 2027.
Impairment loss¥1,399 million. Asset subject to impairment: Not disclosed
Depreciation and amortization¥58,706 million (depreciation and amortization)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End381,587,374 shares
Treasury Shares at Period-End20,060,171 shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsIFRS
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 September 2026
Net Sales¥979,082 million (YoY +20.3%)
Operating profit¥93,764 million (YoY +235.6%)
Ordinary income90,581 Millions of yen (interim profit before tax) (YoY +246.2%)
Profit attributable to owners of the parent¥58,822 million (YoY +650.0%)
Net income per share¥162.71
Equity ratioEnd of the current fiscal period 35.9% / End of previous period 40.2%
Total assets¥2,476,740 million
Net assets¥1,041,621 million (total equity)
Cash flows from operating activities¥91,087 million
Cash flows from investing activities¥-181,174 million
Cash flows from financing activities¥114,159 million
Cash and cash equivalents at end of period¥205,131 million
Full-year earnings forecastNet Sales ¥2,095,000 million (YoY +25.5%) / Core operating profit ¥150,000 million (YoY +50.0%) / Operating profit ¥112,000 million (YoY +51.7%) / Ordinary income ¥101,000 million (profit before tax) / Profit for the period ¥70,000 million (YoY +49.2%) / Profit for the year attributable to owners of the parent ¥53,000 million (YoY +54.2%)
Revision to Earnings ForecastRevenue ¥19,000 billion → ¥20,950 billion(+10.3%) / Core operating profit ¥1,050 billion → ¥1,500 billion(+42.9%) / Operating profit ¥830 billion → ¥1,120 billion(+34.9%) / Profit for the period ¥550 billion → ¥700 billion(+27.3%) / Profit for the year attributable to owners of the parent ¥450 billion → ¥530 billion(+17.8%)
Annual Dividend Forecast¥75 per share (adjusted for the stock split) → ¥75 per share (adjusted for the stock split)(0.0%)
Segment revenueLife & Healthcare Solutions ¥134,564 million, Mobility Solutions ¥300,424 million, ICT Solutions ¥159,258 million, Basic & Green Materials ¥376,486 million, Other ¥8,350 million
Segment profitLife & Healthcare Solutions ¥12,742 million (core operating profit), Mobility Solutions ¥36,545 million (core operating profit), ICT Solutions ¥24,787 million (core operating profit), Basic & Green Materials ¥28,238 million (core operating profit), Other ¥258 million (core operating profit)
Depreciation and amortization¥58,706 million (depreciation and amortization)
Impairment loss¥1,399 million. Asset subject to impairment: Not disclosed
Disclosure regarding the going concern assumptionNo applicable items
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew Number of companies 21 / Company name MC Dental Holdings America, Inc., Ultradent Products, Inc. and 19 subsidiaries / Excluded Number of companies 0 / Company name No
Material subsequent eventsA share transfer agreement for JSR Corporation was signed, and the transaction to make JSR Corporation a consolidated subsidiary was approved on 9 November 2026. The acquisition price is expected to be ¥1.84 trillion, with completion targeted for the second half of fiscal 2027.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End381,587,374 shares
Treasury Shares at Period-End20,060,171 shares
Factors Behind Changes in Business PerformanceRevenue increased due to price revisions in response to higher raw material prices, including naphtha, and foreign exchange differences. Core operating profit increased due to improved inventory valuation gains and losses and improved terms of trade resulting from price revisions. At the segment level, the factors cited include the consolidation of Ultradent as a subsidiary, the benefits of integrating the domestic polyolefin business, business structure improvements, and improved terms of trade resulting from higher raw material prices.
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogBreakdown of extraordinary income (loss)

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue and each profit measure are expected to exceed the previously announced forecasts, due to improved terms of trade resulting from price revisions in response to higher raw material prices, including naphtha, improved inventory valuation gains and losses, foreign exchange differences and other factors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 2027 [IFRS] | Mitsui Chemicals,Inc. (4183) timely disclosure | Komori